Orum Therapeutics Company Description

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases.

The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor.

It also develops multiple programs; and E3 Ligase-DAC adaptor. The company was founded in 2016 and is headquartered in Daejeon, South Korea.